Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 10,628 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more

Conditions: Schizophrenia
Interventions: active intermittent Theta Burst Stimulation (iTBS), sham intermittent Theta Burst Stimulation (iTBS); Device
Lead sponsor: Fabio Ferrarelli; Other
Eligibility: 18 Years to 40 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 15 Months
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more

Conditions: Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
Interventions: TH-4000 (Tarloxotinib); Drug
Lead sponsor: Rain Oncology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more

Conditions: Hodgkin Disease
Interventions: Nivolumab, brentuximab vedotin, bendamustine; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 30 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more

Conditions: Stroke, Acute Ischemic
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Asthma
Interventions: albuterol sulfate inhalation aerosol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 23 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 92
States / cities: Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more

Conditions: Depression
Interventions: Escitalopram, Interpersonal Psychotherapy, Clinical Monitoring; Drug · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Total Knee Arthroplasty Postoperative Pain, Opioid Reduction After TKA
Interventions: NEUROCUPLE™ Patch, Sham patch, Enhanced Recovery After Surgery (ERAS) Standard of Care; Device · Other
Lead sponsor: Jacques E. Chelly; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Esophagus Cancer, Esophageal Cancer, Esophageal Neoplasms, Esophageal Diseases, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophagus SCC, Esophagus Tumor, Esophagus Adenocarcinoma, Esophagus Neoplasm
Interventions: ActivSight; Device
Lead sponsor: Activ Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer of the Pancreas, Pancreatic Cancer, Pancreas Neoplasms, Pancreatic Carcinoma Stage I, Pancreatic Carcinoma Stage II
Interventions: PancreaSure; Diagnostic Test
Lead sponsor: Immunovia, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • New York, New York • Pittsburgh, Pennsylvania + 3 more

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more

Conditions: Opioid-use Disorder, Pregnancy Related
Interventions: OUD; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obesity, Weight Loss
Interventions: behavior weight loss; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Diseases, Interstitial
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2035
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Burnout, Professional
Interventions: Apollo Wearable; Device
Lead sponsor: Michelle Thompson; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD)
Interventions: alglucosidase alfa; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 8 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 26
States / cities: Anchorage, Alaska • Phoenix, Arizona • Beverly Hills, California + 23 more

Conditions: Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
Interventions: CX 4945; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more

Conditions: Concussion Mild
Interventions: Yoga, Yoga for wait list control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 4,125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 34
States / cities: Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more

Conditions: HIV Prevention, Substance Use
Interventions: LYNX, Standard of Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 29 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Autism Spectrum Disorder
Interventions: Placebo, RO5285119; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 45
States / cities: Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more

Search by objective public record fields.

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Posterior cerebraL ArTery Occlusion Study

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression

NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty

Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans

Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Quantitative Sensory Psychophysical Correlates of Pain in Pregnant Women With OUD

Dose-Response of Exercise on Long-Term Weight Loss

Dorothy P. and Richard P. Simmons Center for ILD Research Registry

Impact of Heart Rate Variability Modulation on Stress Management Among Physicians

Late-Onset Treatment Study Extension Protocol

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Yoga and Female Concussion

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

mHealth Service Linkage for Young Adults Impacted by the Criminal Legal System

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)